

This is a promotional Webinar intended for UK healthcare professionals only, organised and funded by Teva UK Limited AJOVY®▼ (fremanezumab) is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month¹

Prescribing Information for AJOVY® is available [here](#)

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Teva UK Limited on [0207 540 7117](tel:02075407117) or medinfo@tevauk.com.



HEAD START

LEADING EDUCATION IN HEADACHE MANAGEMENT

INVITATION

LIVE WEBINARS!

REGISTER NOW!

Migraine mAbs in Pain Clinics: From Theory to Practical Tips

**THURSDAY 02 MARCH 2023
18:00 – 19:00**

UK healthcare professionals are invited to join us at our **live Webinar** with interactive Q&A. **Space is limited** so register early to avoid disappointment!

Learn how and why the use of anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) in pain clinics can optimise migraine management.



Chair

Dr Vivek Mehta

*Consultant in Pain Medicine
Barts Health NHS Trust*



CGRP as a therapeutic target in migraine

Prof Anthony Dickenson

*Emeritus Professor of Neuropharmacology
University College London*



Practical use of anti-CGRP mAbs

Dr Brendan Davies

*Consultant Neurologist
University Hospitals of North Midlands NHS Trust*

Only limited spaces available so register now via www.tevauk.com/hcp/headstart/head-start-webinar or speak to your Teva representative!

If you have any questions about the Head Start Webinars, wish to cancel your registration, or unsubscribe from our mailing list, please e-mail: headstart@violicom.co.uk

This promotional Webinar is organised and funded by Teva UK Limited

References: 1. AJOVY® Summary of Product Characteristics. Teva UK Limited

Teva UK Limited

Ridings Point, Whistler Drive, Castleford, West Yorkshire, WF10 5HX
+44 (0) 1977 628500 | www.tevauk.com

teva

MIG-GB-00179

Date of Preparation: December 2022